Loading...
Antibodies to infliximab are associated with loss of response in patients with inflammatory bowel disease (IBD). The incidence of anti-infliximab antibody development is lower in patients receiving concomitant immunomodulator therapy. To better understand that association as well as the evolution of anti-infliximab antibody development, investigators prospectively studied 125 patients with IBD (98 with Crohn disease and 27 with ulcerative colitis) who received infliximab therapy during a 4-year period.
Median follow-up was 11.5 months. At 4 years, 42% of patients remained free of anti-infliximab antibodies. Among patients who developed infliximab antibodies, 90% did so during the first 12 months of treatment. In survival analysis, time to de…